Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Oct 8;81(1):56–67. doi: 10.1136/annrheumdis-2021-220308

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

In vitro treatment of healthy leucocytes with ACPAs modify the expression of the spliceosome signature along with their associated inflammatory profile. Monocytes (A, D), lymphocytes (B, E) and neutrophils (C, F) from healthy donors were treated with 10 μg/mL of either IgG-ACPA purified from patients with RA through CCP-affinity column chromatography (IgG-ACPAs(+)) or the flow through depleted in Ig-ACPAs (IgG-ACPAs(-)) for 24 in monocytes and lymphocytes and 6 hours in neutrophils. Spliceosome components (A, B, C) and inflammatory molecules (D, E, F) were analysed by RT-PCR. Data from five independent experiments carried out in triplicate are shown. *p<0.05, **p<0.01. ACPAs, anti-citrullinated protein antibodies; IL, interleukin; TNF, tumour necrosis factor.